Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: A population-based study in middle-aged men

Cancer Causes and Control

Volumn 18, Issue 9, 2007, Pages 931-937

  Agalliu, Ilir ^a   Weiss, Noel S ^a,b   Lin, Daniel W ^a,c   Stanford, Janet L ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Digital rectal examination; Prostate cancer screening; Prostate cancer specific mortality; Prostate specific antigen (PSA) test

Indexed keywords

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER;

CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; HUMANS; INTERVIEWS AS TOPIC; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PALPATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34547822992     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-007-9031-7     Document Type: Article

References (25)

1. American Cancer Society (2007) Cancer Facts and Figures
2. De Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S et al (2002) Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 97:237-244
3. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF et al (2005) Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97: 433-438
4. Friedman GD, Hiatt RA, Quesenberry CP, Selby JV (1991) Case-control study of screening for prostate cancer by digital rectal examination. Lancet 337:1526-1529
5. Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, Oesterling JE, Lieber MM (1998) Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 52:173-179
6. Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS (1998) Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen 5:99-103
7. Perron L, Moore L, Bairati I, Bernard PM, Meyer F (2002) PSA screening and prostate cancer mortality. CMAJ 166:586-591
8. Weinmann S, Richert-Boe KE, Glass AG, Weiss NS (2004) Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control 14:133-138
9. Weinmann S, Richert-Boe KE, Van Den Eeden SK, Enger SM, Rybicki BA, Shapiro JA, Weiss NS (2005) Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study. Epidemiology 16:367-376
10. Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N (2005) Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol 174:495-449
11. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P (2001) Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58:417-424
12. Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P, Bartsch G (2005) Screening for prostate cancer: updated experience from the Tyrol study. Can J Urol 12(Suppl 1):7-13
13. Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G (2006) Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 164:376-384
14. Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P (2006) The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med 166:38-43
15. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Levesque J, Belanger A (1999) Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38:83-91
16. Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, Chevrette E, Levesque J (2004) Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59:311-388
17. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P (2004) Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 46:717-723; discussion 724
18. Schroder FH, Roobol MJ, Damhuis RA, de Koning HJ, Blijenberg BG, Van der Kwast TH, Kirkels WJ, Bangma CH (2005) Rotterdam randomized pilot studies of screening for prostate cancer-an overview after 10 years. J Natl Cancer Inst 97:696
19. Ciatto S, Gervasi G, Gorini G, Lombardi C, Zappa M, Crocetti E (2006) Prostate cancer specific mortality in the florence screening pilot study cohort 1992-1993. Eur J Cancer 42:1858-1862
20. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK (1999) Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8:881-886
21. Breslow NE, Day NE (1980) Statistical methods in cancer research, Volume 1. The analysis of case-control studies. International Agency for Research on Cancer, Lyon
22. Smith RA, Cokkinides V, Eyre HJ (2005) American cancer society guidelines for the early detection of cancer, 2005. CA Cancer J Clin 55:31-44
23. Weiss NS (1994) Application of the case-control method in the evaluation of screening. Am J Epidemiology 16:102-108
24. Weiss NS, Etzioni R (2002) Estimating the influence of rescreening interval on the benefits associated with cancer screening: approaches and limitation. Epidemiology 13:713-717
25. Weiss NS, Lazovich DA (1996) Case-control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Am J Epidemiol 143:319-322